Celldex Therapeutics CLDX Grant — Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Celldex Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Celldex Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Celldex Therapeutics's grant — revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Celldex Therapeutics's grant — revenue?
- Celldex Therapeutics (CLDX) reported grant — revenue of $15K in Q1 2026.
- How has Celldex Therapeutics's grant — revenue changed year-over-year?
- Celldex Therapeutics's grant — revenue decreased by 97.7% year-over-year, from $645K to $15K.
- What is the long-term trend for Celldex Therapeutics's grant — revenue?
- Over 4 years (2021 to 2025), Celldex Therapeutics's grant — revenue has grown at a -25.6% compound annual growth rate (CAGR), from $4.62M to $1.42M.
- What does grant — revenue mean?
- This metric represents the revenue recognized from government or institutional grants awarded to support specific research and development activities. It reflects the company's ability to secure non-dilutive funding to offset the costs of advancing its clinical pipeline and immunotherapy technologies. Fluctuations in this metric indicate the timing and volume of research milestones achieved under collaborative or grant-funded agreements.